Innovation Pharmaceuticals Inc (IPIX)

[stevo99]

Not only is K bioavailability much better than Ibrutinib, hopefully the list of side effects will be much lower. Also I really like this part (hopefully prices have gone up since 2011)..."In 2011 after the drug had completed Phase II trials, Johnson & Johnson and Pharmacyclics agreed to co-develop the drug, and J&J paid paid Pharmacyclics $150 million upfront and $825 million in milestones."

Medical use
Ibrutinib is used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia.[2][3]

Adverse effects
Very common (>10% frequency) adverse effects include pneumonia, upper respiratory tract infection, sinusitis, skin infection, low neutrophil count, low platelet counts, headache, bleeding, bruising, diarrhea, vomiting, inflammation of mouth and lips, nausea, constipation, rash, joint pain, muscle spasms, musculoskeletal pain, fever, and edema.[2]

Common (1–10% frequency) adverse effects include sepsis, urinary tract infection, non-melanoma skin cancer (basal-cell carcinoma, squamous cell carcinoma), low leukocyte count, low lymphocyte count, interstitial lung disease, tumor lysis syndrome, high uric acid levels, dizziness, blurred vision, atrial fibrillation subdural hematoma, nosebleeds, small bruises from broken blood vessels, high blood pressure, hives, and skin redness or blushing.[2]